OncoMatch/Clinical Trials/NCT06186401
Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells
Is NCT06186401 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies multiple treatments including E-SYNC T Cells and Cyclophosphamide (non-investigational) for egfr gene mutation.
Treatment: E-SYNC T Cells · Cyclophosphamide (non-investigational) · Fludarabine (non-investigational) — This phase I trial tests the safety, side effects, and best dose of E-SYNC chimeric antigen receptor (CAR) T cells after lymphodepleting chemotherapy in treating patients with EGFRvIII positive (+) glioblastoma. Chimeric antigen receptor (CAR) T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so the CAR T cells will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Lymphodepleting chemotherapy with cyclophosphamide and fludarabine before treatment with CAR T cells may make the CAR T cells more effective.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Glioblastoma
Biomarker criteria
Required: EGFR egfrviii
Pathological criteria: EGFRvIII+ GBM from most recent surgery, confirmed by a Clinical Laboratory Improvement Amendments (CLIA)-certified lab using a next-generation sequencing panel.
Required: MGMT promoter unmethylated or methylation index < 3
MGMT promoter must be unmethylated or with a methylation index < 3.
Prior therapy
Must have received: external beam radiotherapy — initial therapy
Must have completed at least standard of care (SOC) external beam radiotherapy (EBRT) as initial therapy.
Cannot have received: EGFR-targeting therapy
Prior treatment with any Epithelial Growth Factor Receptor (EGFR)-targeting therapy.
Cannot have received: EGFR-targeting therapy
Prior treatment with any EGFR-targeting therapy
Cannot have received: solid organ or bone marrow transplantation
Participants who have received prior solid organ or bone marrow transplantation.
Lab requirements
Blood counts
ANC >= 1000/mm^3; Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment); ALC >= 300/μL and/or CD3 count >= 150/μL
Kidney function
Creatinine clearance or radioisotope GFR >= 50 mL/min/1.73m^2
Liver function
Total Bilirubin <= 1.5 x ULN except for Gilbert's syndrome; ALT and AST <= 3x ULN
Cardiac function
LVEF >= 50% by echocardiogram or MUGA (Cohort 1); LVEF >= 40% by echocardiogram or MUGA (Cohort 2, within last 12 months)
All participants must have adequate organ function defined as: Peripheral absolute neutrophil count >=1000/mm^3; Platelet count >=100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment); Absolute lymphocyte count (ALC) >= 300/μL and/or Cluster of differentiation 3 (CD3) count of >=150/μL. Creatinine clearance or radioisotope glomerular filtration rate >= 50 mL/min/1.73m^2. Total Bilirubin <= 1.5 x ULN except for Gilbert's syndrome and Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 3x upper limit of normal (ULN). Left ventricular ejection fraction (LVEF) >= 50% by echocardiogram or multi-gated acquisition scanning (MUGA). Adequate pulmonary function, defined as no evidence of dyspnea at rest and pulse oximetry > 92% while breathing room air.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, San Francisco · San Francisco, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06186401 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior EGFR-targeting therapy, EGFR-targeting therapy, solid organ or bone marrow transplantation disqualifies patients from enrollment.
Does this trial require EGFR?
Yes, EGFR egfrviii is a required biomarker for enrollment.
Does this trial require MGMT?
Yes, MGMT promoter unmethylated or methylation index < 3 is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify